Glaucoma News and Research

Latest Glaucoma News and Research

UH vision scientist hopes techniques lead to earlier diagnoses in glaucoma

A University of Houston (UH) vision scientist has received a $1.85 million grant from the National Institutes of Health (NIH) to investigate whether his techniques are more effective than others in understanding the earliest changes of glaucoma, which could lead to developing a way to earlier diagnose this potentially blinding disease.

27 Jan 2012

Montefiore vision experts encourage public to learn more about glaucoma

January is National Glaucoma Awareness Month. Vision experts at Montefiore Medical Center encourage the public to learn more about this disease, which is the leading cause of preventable blindness in the United States.

24 Jan 2012

RPB awards $220,000 to SUNY Downstate for eye research

Capping SUNY Downstate Medical Center's growth into a major center for eye research, Research to Prevent Blindness (RPB) has awarded SUNY Downstate a four-year challenge grant of $220,000 to spur the development of advanced research into the causes, treatment, and prevention of blinding diseases. Douglas R. Lazzaro, MD, professor and chair of ophthalmology, is the principal investigator.

24 Jan 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

Georgia Tech findings advance glaucoma research

Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent. New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.

18 Jan 2012

New computational modeling methods book for ophthalmologists

Dr. Sumeet Dua, the Upchurch Endowed Professor of Computer Science and coordinator of information technology research at Louisiana Tech University, has co-edited a new book on computational modeling methods that can help ophthalmologists develop innovative computer systems to provide critical support and better care options for patients.

18 Jan 2012

IUPUI launches Institute for Mathematical Modeling and Computational Science

The School of Science at Indiana University-Purdue University Indianapolis has launched the Institute for Mathematical Modeling and Computational Science, an interdisciplinary endeavor dedicated to solving perplexing problems in such diverse fields as medicine, the environment, and computer science. iM2CS's parallel mission is to train a new generation to identify and solve the scientific issues with which they will be faced.

11 Jan 2012

Clearside Biomedical receives $4M venture capital investment

Technology developed by researchers at the Georgia Institute of Technology and Emory University for delivering drugs and other therapeutics to specific locations in the eye provides the foundation for a startup company that has received a $4 million venture capital investment.

6 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Study finds risk factors associated with exfoliation syndrome

When it comes to whether or not you will develop exfoliation syndrome (ES) -- an eye condition that is a leading cause of secondary open-angle glaucoma and increased risk of cataract as well as cataract surgery complications -- age, gender and where you live does matter.

2 Jan 2012

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management Inc. announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome.

21 Dec 2011

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Pfizer Inc. announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.

6 Dec 2011

U.S. Marshals seize all Syntec's dietary supplements for false claims

U.S. Marshals, at the request of the FDA, today seized all dietary supplements by a Wisconsin maker for false claims made about their safety and effectiveness in treating a number of diseases.

2 Dec 2011

AHAF: Requests for ADR research grants increase by 33% this year

The American Health Assistance Foundation (AHAF), a nonprofit organization funding innovative research through its Alzheimer's Disease Research (ADR) program, today announced that the number of scientists seeking ADR research grants through its annual application process increased by 33% this year.

11 Nov 2011

ACADIA third quarter revenues decrease to $584,000

9 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

Laser therapy to turn brown eyes blue

A laser treatment developed by Stroma Medical's Dr. Gregg Homer takes only 20 seconds to perform but can turn brown eyes into blue ones permanently.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.

3 Nov 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011